Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it-Reference-Cited by-同舟云学术

Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it

Published:2017-01-04 Issue:6 Volume:19 Page:658-666
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Drizou M.,Kotteas E. A.,Syrigos N.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-016-1605-y.pdf

Reference93 articles.

1. Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. Ca Cancer J Clin. 2016;66:7–30.

3. Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge DR et al. Non-small-cell lung cancer, Version 6.2015. Featured updates to the NCCN guidelines. JNCCN. 2015;13(5):517–21.

4. Candarella S, Johnson B. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med. 2013;188(7):770–5.

5. Awad M, Shaw AT. ALK inhibitors in non-small-cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12(7):429–39.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study;Asia-Pacific Journal of Clinical Oncology;2024-06-19

2. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09

3. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25

4. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer;Molecular Biomedicine;2022-12-12

5. Emerging genetic biomarkers in lung adenocarcinoma;SAGE Open Medicine;2022-01